Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 4
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Use COVID-19 filters from PubMed Clinical Queries to refine your search See more SARS-CoV-2 literature, sequence, and clinical content from NCBI
Results by year
Filters applied: . Clear all
Page 1
MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
Boudewijns R, Pérez P, Lázaro-Frías A, Van Looveren D, Vercruysse T, Thibaut HJ, Weynand B, Coelmont L, Neyts J, Astorgano D, Montenegro D, Puentes E, Rodríguez E, Dallmeier K, Esteban M, García-Arriaza J. Boudewijns R, et al. Front Immunol. 2022 Mar 16;13:845969. doi: 10.3389/fimmu.2022.845969. eCollection 2022. Front Immunol. 2022. PMID: 35371064 Free PMC article.
In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). ...Mo …
In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia viru …
Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice.
Lázaro-Frías A, Pérez P, Zamora C, Sánchez-Cordón PJ, Guzmán M, Luczkowiak J, Delgado R, Casasnovas JM, Esteban M, García-Arriaza J. Lázaro-Frías A, et al. NPJ Vaccines. 2022 Feb 9;7(1):17. doi: 10.1038/s41541-022-00440-w. NPJ Vaccines. 2022. PMID: 35140227 Free PMC article.
Two doses of the MVA-CoV2-S vaccine candidate expressing the SARS-CoV-2 spike (S) protein protected K18-hACE2 transgenic mice from a lethal dose of SARS-CoV-2. ...The efficacy and immunological benefits of the MVA-CoV2-S vaccine ca …
Two doses of the MVA-CoV2-S vaccine candidate expressing the SARS-CoV-2 spike (S) protein protected K18-hACE2 tr …
Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate.
Villadiego J, García-Arriaza J, Ramírez-Lorca R, García-Swinburn R, Cabello-Rivera D, Rosales-Nieves AE, Álvarez-Vergara MI, Cala-Fernández F, García-Roldán E, López-Ogáyar JL, Zamora C, Astorgano D, Albericio G, Pérez P, Muñoz-Cabello AM, Pascual A, Esteban M, López-Barneo J, Toledo-Aral JJ. Villadiego J, et al. Nat Neurosci. 2023 Jan 9. doi: 10.1038/s41593-022-01242-y. Online ahead of print. Nat Neurosci. 2023. PMID: 36624276
SARS-CoV-2 brain replication occurs primarily in neurons, leading to neuronal loss, signs of glial activation and vascular damage in mice infected with SARS-CoV-2. One or two doses of a modified vaccinia virus Ankara (MVA) vector expressing the SARS-CoV-2 spike (S) …
SARS-CoV-2 brain replication occurs primarily in neurons, leading to neuronal loss, signs of glial activation and vascular damage in mice in …
A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P, Lázaro-Frías A, Zamora C, Sánchez-Cordón PJ, Astorgano D, Luczkowiak J, Delgado R, Casasnovas JM, Esteban M, García-Arriaza J. Pérez P, et al. Front Immunol. 2022 Jan 27;12:824728. doi: 10.3389/fimmu.2021.824728. eCollection 2021. Front Immunol. 2022. PMID: 35154086 Free PMC article.
One single dose of MVA-CoV2-S(3P) induced higher IgG and neutralizing antibody titers against parental SARS-CoV-2 and variants of concern than MVA-CoV2-S in wild-type C57BL/6 and in transgenic K18-hACE2 mice. In immunized C57BL/6 mice, tw …
One single dose of MVA-CoV2-S(3P) induced higher IgG and neutralizing antibody titers against parental SARS-CoV-2 and v …
COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
García-Arriaza J, Garaigorta U, Pérez P, Lázaro-Frías A, Zamora C, Gastaminza P, Del Fresno C, Casasnovas JM, Sorzano CÓS, Sancho D, Esteban M. García-Arriaza J, et al. J Virol. 2021 Jan 7;95(7):e02260-20. doi: 10.1128/JVI.02260-20. Online ahead of print. J Virol. 2021. PMID: 33414159 Free PMC article.
We developed two COVID-19 vaccines based on modified vaccinia virus Ankara (MVA) vectors expressing the entire SARS-CoV-2 spike (S) protein (MVA-CoV2-S); their immunogenicity was evaluated in mice using DNA/MVA or MVA/MVA pr …
We developed two COVID-19 vaccines based on modified vaccinia virus Ankara (MVA) vectors expressing the entire SARS-CoV-2 spike (S …
Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy.
Lennol MP, García-Ayllón MS, Esteban M, García-Arriaza J, Sáez-Valero J. Lennol MP, et al. Front Immunol. 2022 Oct 12;13:1001951. doi: 10.3389/fimmu.2022.1001951. eCollection 2022. Front Immunol. 2022. PMID: 36311758 Free PMC article.
The circulating full-length ACE2 form displayed a sizable peak at day 4, which declined at day 6 post-challenge. Noticeably, immunization with two doses of the MVA-CoV2-S vaccine candidate prevented ACE2 cleaved changes in serum of animals challenged with a l …
The circulating full-length ACE2 form displayed a sizable peak at day 4, which declined at day 6 post-challenge. Noticeably, immunization wi …